Log in

Aquestive Therapeutics Stock Forecast, Price & News

-0.38 (-4.29 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $8.48
50-Day Range
MA: $7.66
52-Week Range
Now: $8.48
Volume1.29 million shs
Average Volume890,791 shs
Market Capitalization$285.10 million
P/E RatioN/A
Dividend YieldN/A
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Read More
Aquestive Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AQST



Sales & Book Value

Annual Sales$52.61 million
Book Value($0.18) per share


Net Income$-66,250,000.00


Market Cap$285.10 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
-0.38 (-4.29 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

How has Aquestive Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AQST stock has increased by 188.4% and is now trading at $8.48.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Aquestive Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aquestive Therapeutics

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Aquestive Therapeutics

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.36. The company earned $21.68 million during the quarter, compared to the consensus estimate of $9.14 million.
View Aquestive Therapeutics' earnings history

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $35-45 million, compared to the consensus revenue estimate of $38.42 million.

What price target have analysts set for AQST?

5 equities research analysts have issued 12-month price objectives for Aquestive Therapeutics' shares. Their forecasts range from $8.00 to $33.00. On average, they expect Aquestive Therapeutics' share price to reach $16.80 in the next twelve months. This suggests a possible upside of 98.1% from the stock's current price.
View analysts' price targets for Aquestive Therapeutics

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,530,000 shares, a decrease of 12.6% from the August 15th total of 1,750,000 shares. Based on an average trading volume of 845,000 shares, the short-interest ratio is presently 1.8 days.
View Aquestive Therapeutics' Short Interest

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), OrganiGram (OGI), BioNano Genomics (BNGO), Novan (NOVN), Outlook Therapeutics (OTLK) and Gran Tierra Energy (GTE).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 62, Pay $859.98k)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 55, Pay $537.15k)
  • Mr. Daniel Barber, Sr. VP & COO (Age 44, Pay $639.97k)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 61)
  • Ms. Lori J. Braender Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (5.21%), Wedbush Securities Inc. (0.41%), Nuveen Asset Management LLC (0.32%), Bank of New York Mellon Corp (0.18%), Charles Schwab Investment Management Inc. (0.16%) and Bank of America Corp DE (0.15%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd and Theresa Wood.
View institutional ownership trends for Aquestive Therapeutics

Which institutional investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., and Bank of Montreal Can. Company insiders that have sold Aquestive Therapeutics company stock in the last year include Alexander Mark Schobel, John T Maxwell, and Keith J Kendall.
View insider buying and selling activity for Aquestive Therapeutics

Which institutional investors are buying Aquestive Therapeutics stock?

AQST stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Wedbush Securities Inc., Engineers Gate Manager LP, Bank of America Corp DE, and Hancock Whitney Corp. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd, and Theresa Wood.
View insider buying and selling activity for Aquestive Therapeutics

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $8.48.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $285.10 million and generates $52.61 million in revenue each year. The company earns $-66,250,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. Aquestive Therapeutics employs 232 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is www.aquestive.com.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.